Related Experiment Videos
High-dose methotrexate in acute lymphocytic leukemia.
Cancer Treatment Reports
|July 1, 1977
Summary
High-dose methotrexate (MTX) achieved therapeutic cerebrospinal fluid (CSF) levels in patients with acute lymphocytic leukemia. Combining high-dose and intrathecal MTX in pediatric patients showed promising safety and efficacy, with low relapse rates.
Area of Science:
- Pharmacokinetics
- Oncology
- Pediatrics
Background:
- Methotrexate (MTX) is a critical chemotherapeutic agent.
- Understanding MTX pharmacokinetics is vital for optimizing treatment efficacy and safety.
- High-dose MTX regimens are employed for various cancers, necessitating careful monitoring of drug distribution.
Purpose of the Study:
- To evaluate the pharmacokinetic profile of high-dose methotrexate (MTX).
- To assess the efficacy and safety of combined high-dose and intrathecal MTX in pediatric acute lymphocytic leukemia (ALL).
- To determine MTX concentrations in cerebrospinal fluid (CSF) following high-dose administration.
Main Methods:
- A pharmacokinetic study involving 60 patients receiving high-dose MTX (500 mg/m2 over 24 hours).
- Analysis of MTX levels in CSF.
- A subset of 40 pediatric ALL patients received simultaneous high-dose and intrathecal MTX.
Main Results:
- High-dose MTX rapidly achieved and maintained therapeutic levels (1.2 X 10(-7) M) in CSF within 10 minutes for 24 hours.
- Combined high-dose and intrathecal MTX resulted in higher CSF MTX concentrations compared to either method alone.
- In pediatric ALL patients, only one systemic and one CNS relapse were observed.
Conclusions:
- High-dose MTX effectively penetrates the CSF.
- The combination of high-dose and intrathecal MTX is a safe and potentially more effective strategy for pediatric ALL.
- Further investigation into this combined regimen is warranted for CNS-directed therapy.